Sponsor: AbbVie, Inc
Sponsor Study ID: M24-427
Study Title: A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
CTO #: 103955
NCT Number: NCT06084481
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Anus; Bladder; Cervix Uteri; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid
Study Objectives: To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC.